Suzhou Zelgen Biopharmaceuticals Co Ltd (SHG:688266) — Market Cap & Net Worth
Market Cap & Net Worth: Suzhou Zelgen Biopharmaceuticals Co Ltd (688266)
Suzhou Zelgen Biopharmaceuticals Co Ltd (SHG:688266) has a market capitalization of $4.27 Billion (CN¥29.21 Billion) as of August 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #3953 globally and #579 in its home market, demonstrating a -16.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Suzhou Zelgen Biopharmaceuticals Co Ltd's stock price CN¥110.35 by its total outstanding shares 264708186 (264.71 Million). See 688266 capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Suzhou Zelgen Biopharmaceuticals Co Ltd Market Cap History: 2020 to 2026
Suzhou Zelgen Biopharmaceuticals Co Ltd's market capitalization history from 2020 to 2026. Data shows growth from $2.51 Billion to $4.27 Billion (6.17% CAGR).
Suzhou Zelgen Biopharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.53x
Suzhou Zelgen Biopharmaceuticals Co Ltd's market cap is 4.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.51 Billion | $27.66 Million | -$319.23 Million | 90.59x | N/A |
| 2021 | $2.28 Billion | $190.36 Million | -$451.00 Million | 11.96x | N/A |
| 2022 | $1.62 Billion | $302.31 Million | -$457.33 Million | 5.34x | N/A |
| 2023 | $2.05 Billion | $386.44 Million | -$278.58 Million | 5.31x | N/A |
| 2024 | $2.41 Billion | $532.95 Million | -$137.83 Million | 4.53x | N/A |
Competitor Companies of 688266 by Market Capitalization
Companies near Suzhou Zelgen Biopharmaceuticals Co Ltd in the global market cap rankings as of August 7, 2026.
Key companies related to Suzhou Zelgen Biopharmaceuticals Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Suzhou Zelgen Biopharmaceuticals Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Suzhou Zelgen Biopharmaceuticals Co Ltd's market cap moved from $2.51 Billion to $ 4.27 Billion, with a yearly change of 6.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.27 Billion | +19.04% |
| 2025 | CN¥3.59 Billion | +48.77% |
| 2024 | CN¥2.41 Billion | +17.70% |
| 2023 | CN¥2.05 Billion | +26.95% |
| 2022 | CN¥1.62 Billion | -29.08% |
| 2021 | CN¥2.28 Billion | -9.10% |
| 2020 | CN¥2.51 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Suzhou Zelgen Biopharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.27 Billion USD |
| MoneyControl | $4.27 Billion USD |
| MarketWatch | $4.27 Billion USD |
| marketcap.company | $4.27 Billion USD |
| Reuters | $4.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more